{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:14:38Z","timestamp":1789071278658,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T00:00:00Z","timestamp":1389571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Laboratory and immunological abnormalities seen in overt macrophage activation syndrome (<jats:styled-content style=\"fixed-case\">MAS<\/jats:styled-content>) may be observed in patients with untreated new onset systemic onset juvenile idiopathic arthritis (So<jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content>). We investigated the prevalence of clinical and traditional laboratory markers of <jats:styled-content style=\"fixed-case\">MAS<\/jats:styled-content> as well as soluble <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>163 and soluble interleukin (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>)\u20102R\u03b1 (<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>25) in active So<jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content> patients<jats:bold>.<\/jats:bold><\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty\u2010three consecutive patients with active So<jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content> (International League of Associations for Rheumatology criteria), 11 patients with active polyarticular <jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content> (poly<jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content>) (disease control) and two patients with <jats:styled-content style=\"fixed-case\">MAS<\/jats:styled-content> with So<jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content> were included in the study. Clinical data, complete blood count, coagulation profile, biochemical tests were performed. Soluble <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>25 and soluble <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>163 levels were estimated by enzyme\u2010linked immunosorbent assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 33 active SoJIA patients, 22 were male, the mean age at onset of disease was 6.77\u00a0\u00b1\u00a04.48\u00a0years and the duration of disease was 4.39\u00a0\u00b1\u00a04.6\u00a0years. Of the 11 polyJIA patients seven were boys. None of the SoJIA patient had clinical features of MAS. Fibrinogen &lt;\u00a02.5\u00a0g\/L was present in 14\/33 patients with SoJIA but in only 1\/11 in polyJIA. Both patients with MAS had thrombocytopenia, leucopenia and reduced fibrinogen levels. <jats:styled-content style=\"fixed-case\">sCD<\/jats:styled-content>25 &gt;\u00a07500\u00a0pg\/mL seen in MAS was present in eight patients with active SoJIA. Among these eight patients, four had multiple laboratory abnormalities suggestive of MAS. Indeed, one of the patients had past history of MAS. Elevated <jats:styled-content style=\"fixed-case\">sCD<\/jats:styled-content>63 (&gt;\u00a01800\u00a0ng\/mL) was seen in four patients with SoJIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Laboratory abnormalities associated with MAS are not uncommon in active SoJIA. Soluble CD25 &gt;\u00a07500\u00a0pg\/mL may be a marker to detect children with subclinical MAS.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12196","type":"journal-article","created":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T07:03:41Z","timestamp":1389596621000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Soluble <scp>CD<\/scp>25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis"],"prefix":"10.1111","volume":"17","author":[{"given":"Vishnu V.","family":"Reddy","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Myles","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanaryan S.","family":"Cheekatla","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32825a6a79"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.12.016"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22416"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20198"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1453"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.110"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.85.5.421"},{"key":"e_1_2_7_10_1","first-page":"RA27","article-title":"Macrophage activation syndrome: a frequent but under\u2010diagnosed complication associated with rheumatic diseases","volume":"14","author":"Tristano AG","year":"2008","journal-title":"Med Sci Monit"},{"key":"e_1_2_7_11_1","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens EM","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24750"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(98)00145-5"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2223\/JPED.1267"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-008-0018-6"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000083450"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2006.tb02414.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1711-z"},{"key":"e_1_2_7_19_1","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2009.08.003"},{"key":"e_1_2_7_21_1","first-page":"451","article-title":"Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases","volume":"11","author":"Stephan JL","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"e_1_2_7_23_1","first-page":"108","article-title":"Dramatic efficacy of cyclosporine. A in macrophage activation syndrome","volume":"19","author":"Ravelli A","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000081259.61370.eb"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem271"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121098"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318205092d"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:04:53Z","timestamp":1695492293000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,13]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/1756-185X.12196"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12196","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,13]]},"assertion":[{"value":"2014-01-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}